MapLight (MPLT) CDO Anatol Kreitzer Receives RSU Award

What Happened Anatol Kreitzer, Chief Discovery Officer of MapLight Therapeutics (MPLT), received equity awards on August 17, 2026 totaling 30,475 units: 6,020 shares listed as acquired and 24,455 listed as a derivative award. Both items were granted at $0.00 (awards, not purchases), so no cash changed hands at grant.

Key Details

• Transaction date: 2026-08-17; Form 4 filed: 2026-08-19 (appears timely within the SEC’s 2-business-day requirement).
• Awards: 6,020 shares (direct RSU grant) + 24,455 derivative RSUs = 30,475 total; reported value at grant = $0.
• Vesting (footnotes): F1/F2 — RSUs: 1/4 vest on July 1, 2027, then 1/16 vest each subsequent Oct 1, Jan 1, Apr 1 and Jul 1 (quarterly) subject to continued service; each RSU converts into one share.
• Additional vesting note (F3): describes a separate option-style vesting schedule (1/4 on July 1, 2027, then 1/48 monthly thereafter) — included in the filing as a vesting term for derivative awards.
• Shares owned after the transaction: not specified in the provided filing excerpt.

Context These entries are awards of restricted stock units (RSUs), meaning Kreitzer has a contingent right to receive shares in the future if vesting conditions are met; they are not open-market purchases or sales. RSU grants are common compensation for executives and do not, by themselves, indicate immediate buying or selling sentiment.